To further assess the combined mTOR inhibition and BCL-XL degradation as a potential therapeutic strategy for BCL-XL and MCL-1 co-dependent SCLC, we first investigated the efficacy of DT2216 + AZD8055 combination using the H1048 xenograft tumor model. This evidence concerns the gene MCL1 and neoplasm.